Antitumor agents 68: effects of a series of helenalin derivatives on P-388 lymphocytic leukemia nucleic acid and protein synthesis. 1985

I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee

A series of analogues related to helenalin demonstrated moderate capability for inhibiting the growth of murine P-388 lymphocytic leukemia cells in vivo and in vitro. The growth inhibition correlated with suppression of both DNA and protein synthesis in P-388 cells. The inhibition of protein synthesis occurred at a relatively low concentration and appeared to occur at the level of initiation. The suppression of DNA synthesis in P-388 cells correlated positively with inhibition of inosine 5'-monophosphate dehydrogenase activity. Although nuclear and alpha DNA polymerase activities were suppressed by certain analogues, the inhibition of the polymerases did not correlate positively with DNA synthesis inhibition and, furthermore, the magnitude of suppression of DNA polymerase activity did not appear to be sufficient to account for the observed suppression of DNA synthesis in P-388 cells.

UI MeSH Term Description Entries
D007168 IMP Dehydrogenase An enzyme that catalyzes the dehydrogenation of inosine 5'-phosphate to xanthosine 5'-phosphate in the presence of NAD. EC 1.1.1.205. Inosinic Acid Dehydrogenase,Inosine-5-Monophosphate Dehydrogenase,Acid Dehydrogenase, Inosinic,Dehydrogenase, IMP,Dehydrogenase, Inosine-5-Monophosphate,Dehydrogenase, Inosinic Acid,Inosine 5 Monophosphate Dehydrogenase
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D007942 Leukemia, Experimental Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues. Experimental Leukemia,Experimental Leukemias,Leukemia Model, Animal,Leukemias, Experimental,Animal Leukemia Model,Animal Leukemia Models,Leukemia Models, Animal
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011687 Purines A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene

Related Publications

I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
November 1982, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
March 1982, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
July 1979, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
December 1982, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
February 1982, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
July 1979, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
October 1981, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
April 1982, Journal of pharmaceutical sciences,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
August 1978, Journal of medicinal chemistry,
I H Hall, and W L Williams, and S G Chaney, and C J Gilbert, and D J Holbrook, and O Muraoka, and H Kiyokawa, and K H Lee
January 1986, Archivum immunologiae et therapiae experimentalis,
Copied contents to your clipboard!